Inactive Instrument

Eidos Therapeutics, Inc.

EIDX

US28249H1041

Biotechnology & Medical Research

Eidos Therapeutics, Inc.(NasdaqGS:EIDX) dropped from S&P TMI Index

January 27, 2021 at 12:00 am EST

Latest news about Eidos Therapeutics, Inc.

Eidos Therapeutics, Inc.(NasdaqGS:EIDX) dropped from S&P TMI Index	21-01-27	CI
Eidos Therapeutics, Inc.(NasdaqGS:EIDX) dropped from S&P Global BMI Index	21-01-27	CI
Eidos Therapeutics, Inc. Announces Board Changes	21-01-26	CI
Eidos Therapeutics, Inc.(NasdaqGM:EIDX) dropped from NASDAQ Composite Index	21-01-26	CI
BridgeBio Pharma, Inc. completed the acquisition of remaining 36.3% stake in Eidos Therapeutics, Inc..	21-01-25	CI
Eidos Therapeutics, Inc.(NasdaqGS:EIDX) dropped from Russell 2000 Index	21-01-25	CI
Eidos Therapeutics, Inc.(NasdaqGS:EIDX) dropped from Russell 3000 Index	21-01-25	CI
Eidos Therapeutics, Inc.(NasdaqGS:EIDX) dropped from Russell 2500 Index	21-01-25	CI
Eidos Therapeutics, Inc.(NasdaqGS:EIDX) dropped from Russell 2000 Growth Index	21-01-25	CI
Eidos Therapeutics, Inc.(NasdaqGS:EIDX) dropped from Russell Small Cap Completeness Index	21-01-25	CI
Eidos Therapeutics, Inc.(NasdaqGS:EIDX) dropped from Russell Small Cap Comp Growth Index	21-01-25	CI
Eidos Therapeutics, Inc.(NasdaqGS:EIDX) dropped from Russell 3000 Growth Index	21-01-25	CI
Eidos Therapeutics, Inc.(NasdaqGS:EIDX) dropped from Russell 2500 Growth Index	21-01-25	CI
Eidos Therapeutics, Inc.(NasdaqGS:EIDX) dropped from Russell 3000E Index	21-01-25	CI
Eidos Therapeutics, Inc.(NasdaqGS:EIDX) dropped from Russell 3000E Growth Index	21-01-25	CI
Eidos Therapeutics, Inc.(NasdaqGS:EIDX) dropped from Russell 2000 Dynamic Index	21-01-25	CI
Eidos Therapeutics, Inc.(NasdaqGS:EIDX) dropped from Russell 2500 Dynamic Index	21-01-25	CI
Eidos Therapeutics, Inc.(NasdaqGS:EIDX) dropped from Russell 2000 Growth-Dynamic Index	21-01-25	CI
Eidos Therapeutics, Inc.(NasdaqGS:EIDX) dropped from Russell 2500 Growth-Dynamic Index	21-01-25	CI
Eidos Therapeutics, Inc.(NasdaqGS:EIDX) dropped from NASDAQ Biotechnology Index	21-01-25	CI
Eidos Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-10-29	CI
Transcript : BridgeBio Pharma, Inc., Eidos Therapeutics, Inc. - M&A Call	20-10-05
BridgeBio Pharma, Inc. entered into a definitive agreement to acquire remaining 36.3% stake in Eidos Therapeutics, Inc. for $1 billion.	20-10-04	CI
Eidos Therapeutics, Inc. Announces Board Changes	20-08-07	CI
Eidos Therapeutics, Inc. Expects Enrollment of Patients in Its Phase 3 Clinical Trial of Acoramidis in ATTR-CM Patients	20-08-06	CI

Chart Eidos Therapeutics, Inc.

Duration

Period

More charts

Eidos Therapeutics, Inc. is a clinical stage biopharmaceutical company. The Company is focused on addressing the unmet need in diseases caused by transthyretin (TTR), amyloidosis (ATTR). It focuses on treating the disease by targeting them at their collective source by stabilizing TTR. The Company's product candidate, AG10, is an orally-administered small molecule designed to potently stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. AG10 binds and stabilizes TTR in the blood, preventing the formation of amyloid and halting progression of the disease.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs